confid acceler clear consist
growth orient tuck-in address diabet shortfal
execut divers pipelin key focu item
incom ceo geoff martha expect growth
ep messag growth like higher
ceo seri omar ishrak geoff martha
ceo seri weekli call ceo across medic devic industri
discuss key structur dynam invest debat recent host
omar ishrak chairman ceo geoff martha presid incom ceo
pipelin renal denerv hugo path recoveri diabet
long-term durabl vs acceler left convers
understand continu uncertainti around cov china
assur volum off-set price dynam nation tender
beyond china confid organ guidanc impli
acceler manag continu target double-digit
return profil expect ep growth guidanc june analyst day
regard pipelin catalyst surgic robot could greatest impact
time frame diabet includ pcl
evolut potenti lesser rel driver next year
uncertainti china price receiv specif disclosur
impact mr ishrak confirm signific pressur februari
guid impact date unlik
receiv updat deeper quarter like april recent note
see experi impact in-lin alcon
other forecast china sale lost februari march
drive growth underli guidanc long-term
nation tender china inevit see suggest risk
out-year china growth low mid-teen recent year
manag see two mitig provinci process margin eros
price larg born distributor manufactur
market under-penetr volum growth provid path doubl
 commentari affirm less like view recent media
report suggest potenti buyer
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
activ recent pick klue stimgenics- see digit
surgeri recent commentari pace continu
said mr martha specif note focus busi
tuck-in size wamgr accret view affirm sens
acquisit less like given growth profil
wamgr outstand trd reimburs necessari drive
faster growth carri risk initi thought hypothet deal
analysi
diabet strategi chang discuss diabet innov gap
potenti need higher reinvest taken
note continu believ diabet busi requir strategi shift
and/or better execut close gap peer especi pertain
sensor technolog near busi today although
aid-approv world pump success increasingli predic sensor
well encourag certain action replac leadership
push manag stay cours spin busi engag
deeper partnership found call instruct direct
mr ishrak mr martha indic sensor technolog show
substanti advanc synergi expect launch
ada whether mean icgm design less like
clear given peer timelin icgm approv libr
convinc icgm event
interoper like longer term requir icgm may
first facilit tidepool loop
relat disrupt action investor intrigu idea
broader partnership abbott sens size
sensor busi integr timelin make less
tenabl mr martha remain open mind diabet spin
believ offer spend strateg flexibl less like
pump remain bright spot slate launch ex-u
quarter us earli manag confirm plan
submit algorithm fda march said traction
may prove flatter without better interoper sensor
manag noncommitt diabet growth origin
guid consid ex-u growth us
defer revenu revers outlook seem reason model
risk asid time remain sensor dynam
enthusiasm pipelin remain focus see diabet
commentari renal denerv spyral off-m data come
gener surgic robot hugo collect catalyst
could gener point growth next three year
hugo excit clear financi expect intact
see deeper-d post-septemb robot day manag see
hugo execut stori confid expand
market develop contrast renal denerv multi-billion
dollar market opportun outstand clinic detail off-m
on-m data requir fda approv reimburs question
speak speed market develop spyral biggest potenti
singl product opportun month post-commerci
look june analyst day enter met
consensu organ growth quarter row durabl
account back focu follow expect commentari
consist analyst day mr martha take helm late april
one initi chang sale manag incent begin
smooth month-to-month revenu reduc emphasi sale last
month quarter extra sell week would boost
inorgan sale uninterrupt scenario like contribut
less impact next year implement initi drive level
sale disrupt
acceler year rel dont expect
initi outlook exceed
still room addit opex effici deliv
bp annual margin expans sinc analyst day
call manag express confid ep growth similar
analyst day drive double-digit total return profil mr
martha indic still room trim cost post-covidien name
 expect select reinvest back limit earn
growth upper singl digit
pipelin support multipl
deriv base case scenario price target reect base-cas
ep discount larg cap peer
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
reset expect
execut organ growth trend
ep growth doubl digit
upsid multipl expand
long-term prole mid-singl
digit organ growth bp
margin expans high-singl digit ep
growth total return prole
pipelin support multipl
rel market vs histor
discount support launch includ
renal denerv surgic robot
see organ revenu guidanc
achiev given comp product
view descript risk reward theme
end market slow take top-line
organ growth fall
underli leverag harder come
given lower growth earn growth
reach mid upper singl digit
top-line growth estim bp
top-line growth contribut ep
margin estim bp ebit margin
drive ep
china india
view explan region hierarchi
research highest favor quintil
pipelin product approv launch
ahead expect
db tavr dcb linq
slowdown acceler emerg market
less repurchas activ materi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
